Comparison of Cardiac Computed Tomographic Angiography (CTA) to Tc-99m Single Photon Emission Computed Tomography (SPECT)

NCT00449943 | Completed

• 1 other identifier: 2006360-01H
• Study Type: interventional
• Target: 107
• Locations: 1 country
• Sites: 1

Brief Summary

Cardiovascular disease and ischemic heart disease is the #1 killer in Canada. Currently, Cardiac invasive catheterization angiography (CICA) is the gold standard for the assessment of the arteries in the heart. However, cardiac catheterization has risks which prohibit its use in all patients. These risks include: death, heart attack, stroke and bleeding. Cardiac computed tomography angiography (CTA) is a new non-invasive technology which may enable the evaluation of patients' coronary anatomy without exposing patients to the risks of invasive cardiac catheterization. The purpose of this project is to compare CT angiography (CTA) to Tc-99m single photon emission computed tomography (Tc-99m SPECT) We will enroll patients who are waiting for a CICA or who have been referred for a TC-99m SPECT or CTA scans at the University of Ottawa Heart Institute. Consenting patients who are waiting for a CICA will have both a CTA and a Tc-99m SPECT scan. Consenting patients referred for a CTA or Tc-99m SPECT will have both the CTA and Tc-99m SPECT in a random order but not CICA (unless ordered by your physician).

Conditions

Coronary Artery Disease

Keywords

Cardiac Invasive Catheterization Angiography; Single Photon Emission Computed Tomography; Computed Tomography Angiography

Outcome Measures

Primary Outcomes (1)

• To measure the accuracy of CTA to SPECT for the diagnosis of CAD

  1 year

Secondary Outcomes (1)

• To examine the accuracy of CTA predicting the mode of treatment: Medical therapy or revascularization (PCI versus CABG)

  1 year

Interventions

Computed Tomographic Angiography PROCEDURE

CT scan

Myocardial Perfusion Imaging Scan PROCEDURE

SPECT

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients referred for Tc-99m SPECT or CTA; or
• Patients referred for CICA without preceding (\< 12 months) MPI or CTA

You may not qualify if:

• Previous revascularization (PCI or CABG)
• Age \< 18 years or lack of consent
• Renal Insufficiency (GFR \< 60 ml/min)
• Allergy or contraindication to contrast agent or dipyridamole
• Refractory angina requiring urgent/emergent coronary angiography
• Contraindication to radiation exposure (e.g. pregnancy)
• Uncontrolled HR
• Atrial fibrillation, frequent atrial or ventricular ectopy (\> 1/minute)
• Unable to perform 10 second breath-hold

Sponsors & Collaborators

• Ottawa Heart Institute Research Corporation: lead

Study Sites (1)

University of Ottawa Heart Institute

Ottawa, Ontario, K1Y 4W7, Canada

Location

Related Links

• University of Ottawa Heart Institute

MeSH Terms

Conditions

Coronary Artery Disease

Condition Hierarchy (Ancestors)

Coronary Disease; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases

Study Officials

• Benjamin JW Chow, MD, FRCPC

  Ottawa Heart Institute Research Corporation

  PRINCIPAL INVESTIGATOR

• Robert Beanlands, MD

  Ottawa Heart Institute Research Corporation

  STUDY CHAIR

• Terrence Ruddy, MD

  Univeristy of Ottawa Heart Institute

  STUDY CHAIR

• Carole Dennie, MD

  The Ottawa Hospital

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD

Study Record Dates

• First Submitted: March 20, 2007
• First Posted: March 21, 2007
• Study Start: September 1, 2006
• Primary Completion: December 1, 2008
• Study Completion: December 1, 2010
• Last Updated: January 26, 2012

Record last verified: 2012-01

Locations

CA (1)